Financhill
Back

NovoCure Quote, Financials, Valuation and Earnings

NovoCure Price Quote

$94.18
-0.04 (-0.96%)
(Updated: February 4, 2023 at 4:26 AM ET)

NovoCure Key Stats

Buy
74
NovoCure (NVCR) is a Buy

Day range:
$92.20 - $95.13
52-week range:
$56.39 - $120.03
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
18.13
P/B ratio:
22.2%

Volume:
743K
Avg. volume:
1.4M
1-year change:
35.92%
Market cap:
$9.9B
Revenue:
$535M
EPS:
$-0.77

How Much Does NovoCure Make?

  • How Much Are NovoCure's Sales Annually?
    NVCR Revenues are $535M
  • How Much Profit Does NovoCure's Make A Year?
    NVCR net income is -$58.4M

Is NovoCure Growing As A Company?

  • What Is NovoCure's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.02%
  • What Is NovoCure's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

NovoCure Stock Price Performance

  • Did NovoCure Stock Go Up Last Month?
    NovoCure share price went up by 38.68% last month
  • Did NVCR's Share Price Rise Over The Last Year?
    NVCR share price rose by 35.92% over the past 1 year

What Is NovoCure 52-Week High & Low?

  • What Is NovoCure’s 52-Week High Share Price?
    NovoCure has traded as high as $120.03 over the past 52 weeks
  • What Is NovoCure’s 52-Week Low Share Price?
    NovoCure has traded as low as $56.39 over the past 52 weeks

NovoCure Price To Free Cash Flow

  • Is NovoCure Stock Overvalued?
    NovoCure is trading at a price to free cash flow ratio of 499.35
  • Is NovoCure Stock Undervalued?
    NovoCure EV to Free Cash Flow ratio is 481.41
  • What Is NovoCure’s Price Earnings Growth Ratio?
    NVCR PEG ratio is -0.66
  • Is NovoCure Trading At A Premium To Earnings?
    NovoCure EV to EBIT ratio is 0.00

Is It Risky To Buy NovoCure?

  • How Much Debt Does NovoCure Have?
    Total long term debt quarterly is $564.7M
  • How Much Cash Does NovoCure Have?
    Cash and short term investments quarterly total is $970.3M
  • What Is NovoCure’s Book Value Per Share?
    Book value per share is 4.24

Is NovoCure Cash Flow Positive?

  • What Is NVCR Cash Flow From Operations?
    Cash flow from operations (TTM) is $48.9M
  • What Is NovoCure’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $15.7M
  • What Is NovoCure’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$511M

NovoCure Return On Invested Capital

  • Is Management Doing A Good Job?
    NVCR return on invested capital is -8.23%
  • What Is NovoCure Return On Assets?
    ROA measures how assets are converting to revenues and is -7.11%
  • What Is NVCR Return On Equity?
    ROE is a measure of profitability and is -19.03%

NovoCure Earnings Date & Stock Price

  • What Is NovoCure's Stock Price Today?
    A single share of NVCR can be purchased today for 94.22
  • What Is NovoCure’s Stock Symbol?
    NovoCure trades on the nasdaq under the ticker symbol: NVCR
  • When Is NovoCure’s Next Earnings Date?
    The next quarterly earnings date for NovoCure is scheduled on February 23, 2023
  • When Is NVCR's next ex-dividend date?
    NovoCure's next ex-dividend date is February 4, 2023
  • How To Buy NovoCure Stock?
    You can buy NovoCure shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

NovoCure Competitors

  • Who Are NovoCure's Competitors?
    Below is a list of companies who compete with NovoCure or are related in some way:
    • Asensus Surgical Inc (ASXC)
    • Boston Scientific Corp (BSX)
    • Isoray Inc (ISR)
    • Insulet Corp (PODD)
    • Xtant Medical Holdings Inc (XTNT)

NovoCure Dividend Yield

Data Unavailable

NovoCure Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.77%
Revenue: -1.95% -1.79%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 3
Sell Recommendations: 2
Price Target: 103.75
Upside from Last Price: 10.11%

Major Shareholders

  • How many NVCR shares are owned by institutional investors?
    170.3M NVCR shares are owned by institutional investors
  • How many NVCR shares are owned by insiders?
    8.1M NVCR shares are owned by insiders